Annals of Oncology Advance Access originally published online on February 25, 2008
Annals of Oncology 2008 19(5):958-963; doi:10.1093/annonc/mdn022
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
hematologic malignancies |
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
1 Departments of Hematology and Pathology, Hospital Clínic
2 Hospital de Sant Pau, Barcelona
3 Hospital Germans Trias I Pujol, Badalona
4 Hospital del Mar, Barcelona
5 Hospital Joan XXIII, Tarragona
6 Hospital Mútua de Terrassa, Terrassa, Spain
* Correspondence to: Dr A. López-Guillermo, Department of Hematology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Tel: +34-932275575; Fax: +34-932275484; E-mail: alopezg{at}clinic.ub.es
Aim: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).
Patients and methods: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m2/day, adriamycin 90 mg/m2/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone. Responders were submitted to ASCT.
Results: Sixty-eight percent of patients received the planned treatment. After chemotherapy, 20 patients reached complete response (CR), 4 partial response and 17 failed. ASCT was carried out in 17 of 24 candidates due to lack of mobilization (three cases), toxicity (two), early relapse and patient decision (one each). CR rate after treatment was 51%. With a median follow-up of 3.2 years, 5 of 21 CR patients relapsed and 2 died in CR due to secondary neoplasms. Four-year progression-free survival was 30%. Twenty-two patients have died, with a 4-year overall survival of 39%. International Prognostic Index was the main variable predicting survival. No differences were seen among the 24 candidates according to whether or not they underwent ASCT.
Conclusion: This intensive regimen resulted in moderate CR rate, with manageable toxicity in PTCL. The contribution of ASCT in preventing relapse is debatable. Novel strategies to increase CR warrant investigation.
Key words: autologous stem-cell transplantation, peripheral T-cell lymphoma, prognosis
Received for publication January 7, 2008. Accepted for publication January 9, 2008.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Nickelsen, M. Ziepert, S. Zeynalova, B. Glass, B. Metzner, M. Leithaeuser, H. K. Mueller-Hermelink, M. Pfreundschuh, and N. Schmitz High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Ann. Onc., December 1, 2009; 20(12): 1977 - 1984. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Moskowitz and C. H. Moskowitz Controversies in the Treatment of Lymphoma with Autologous Transplantation Oncologist, September 1, 2009; 14(9): 921 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study J. Clin. Oncol., January 1, 2009; 27(1): 106 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Foss Treatment Approaches for Aggressive T-cell Lymphomas ASCO Educational Book, January 1, 2009; 2009(1): 480 - 485. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Shustov and K. J. Savage Does High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation Have a Role in the Primary Treatment of Peripheral T-Cell Lymphomas? Hematology, January 1, 2008; 2008(1): 39 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Horwitz Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 289 - 296. [Abstract] [Full Text] [PDF] |
||||




